Krishnan Syam, Shetty Kuldeep, Puthanveedu Divya Kalikavil, Kesavapisharady Krishnakumar, Thulaseedharan Jissa Vinoda, Sarma Gangadhara, Kishore Asha
Comprehensive Care Centre for Movement Disorders Sree Chitra Tirunal Institute for Medical Sciences and Technology Thiruvananthapuram Kerala India.
Department of Neurosurgery Sree Chitra Tirunal Institute for Medical Sciences and Technology Thiruvananthapuram Kerala India.
Mov Disord Clin Pract. 2021 Apr 12;8(4):587-593. doi: 10.1002/mdc3.13206. eCollection 2021 May.
New-onset apraxia of lid opening (ALO) is reported to occur in Parkinson's disease (PD) patients following Deep Brain Stimulation (DBS). There are only few systematic studies on this uncommon disorder of eyelid movements.
We aimed to examine the frequency, temporal evolution, predisposing factors and response to treatment, of new-onset ALO in PD patients who underwent bilateral subthalamic nucleus (STN) DBS.
We retrospectively reviewed the data of patients who underwent STN DBS at our centre between 1999 and 2017, with a minimum of 2 years of follow up after surgery.
New-onset ALO was seen in 17 (9.1%) of the 187 patients after an average of 16.9 months (Range - 6-36 months). Comparison of the groups with and without ALO revealed that ALO occurred more often in older patients, both at the onset of PD symptoms and at surgery and in those with non-tremor dominant subtypes of PD and freezing of gait at baseline. The extent of levodopa dose reduction after surgery and the pre-operative severity of motor symptoms were not risk factors. Response to adjustments of dopaminergic medications and stimulation parameters was ill-sustained or nil. Botulinum toxin therapy resulted in satisfactory improvement in the majority.
New-onset ALO is an uncommon phenomenon that manifests months after STN DBS. Development of ALO is likely to be due to the effects of chronic stimulation of basal ganglia-thalamo-cortical or brain stem circuits controlling lid movements in susceptible patients. Botulinum toxin therapy offers relatively better relief of symptoms than other strategies.
据报道,帕金森病(PD)患者在接受脑深部电刺激(DBS)后会出现新发眼睑开合失用症(ALO)。关于这种罕见的眼睑运动障碍,仅有少数系统研究。
我们旨在研究接受双侧丘脑底核(STN)DBS的PD患者中,新发ALO的发生率、时间演变、诱发因素及治疗反应。
我们回顾性分析了1999年至2017年间在我们中心接受STN DBS治疗的患者数据,术后至少随访2年。
187例患者中有17例(9.1%)出现新发ALO,平均发生时间为16.9个月(范围6 - 36个月)。对有和没有ALO的两组患者进行比较发现,ALO在老年患者中更常见,无论是在PD症状出现时还是手术时,以及那些以非震颤为主型PD且基线时有步态冻结的患者中。术后左旋多巴剂量减少的程度和术前运动症状的严重程度不是危险因素。对多巴胺能药物和刺激参数调整的反应持续不佳或无反应。肉毒毒素治疗使大多数患者症状得到满意改善。
新发ALO是一种罕见现象,在STN DBS术后数月出现。ALO的发生可能是由于对易感患者控制眼睑运动的基底神经节 - 丘脑 - 皮质或脑干回路进行慢性刺激的结果。与其他策略相比,肉毒毒素治疗能更好地缓解症状。